Biogen (BIIB) Tops Q2 EPS by $1.12; Raises Outlook
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $199.96 +2.94%
Revenue Growth %: -6.5%
Financial Fact:
Net income attributable to Biogen Idec Inc.: 1.03B
Today's EPS Names:
CRMT, REPL, ANIX, More
Revenue Growth %: -6.5%
Financial Fact:
Net income attributable to Biogen Idec Inc.: 1.03B
Today's EPS Names:
CRMT, REPL, ANIX, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q2 EPS of $5.25, $1.12 better than the analyst estimate of $4.13. Revenue for the quarter came in at $2.59 billion versus the consensus estimate of $2.49 billion.
GUIDANCE:
Biogen sees FY2022 EPS of $15.25-$16.75, versus the consensus of $15.54. Biogen sees FY2022 revenue of $9.9-10.1 billion, versus the consensus of $9.84 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RH (RH) Tops Q1 EPS by 12c
- Barclays Upgrades Avanza Bank Holding AB (AZA:SS) to Overweight
- Stitch Fix (SFIX) Tops Q3 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
